Amorepacific Swings To Profit In Q4

Amorepacific Holdings reported a turnaround to a small net profit in Q4, with net income attributable to shareholders of KRW 2.95 billion versus a loss of KRW 6.34 billion a year earlier, while net sales rose to KRW 1.26 trillion from KRW 1.18 trillion. Operating income, however, fell 30.7% to KRW 54.76 billion from KRW 79.03 billion, indicating margin pressure despite top-line growth; the stock was trading down about 1.78% at KRW 12,160. The results suggest modest profitability recovery but weaker operating performance, likely limiting near-term market reaction.

Analysis

Market structure: Amorepacific reported +6.8% YoY sales growth to KRW 1.26t but operating income fell 30.7% to KRW 54.76b and net income barely positive KRW 2.95b, signalling revenue resilience but margin compression (current operating margin ~4.3%). Winners: suppliers of higher-margin SKUs and travel-retail channels if demand rebounds; losers: mid-tier mass brands and distributors that compete on price. Expect pricing power constrained near-term; upside requires a >200bp margin recovery to re-rate the stock materially.

Risk assessment: Key tail risks are a renewed Chinese demand collapse (>-10% YoY cosmetics sales) or KRW depreciation >5% in 3 months that raises input/import costs; regulatory recalls could produce >10% EPS hit. Immediate (days) risks: knee-jerk volatility around guidance; short-term (weeks–months): margin trajectory and inventory digestion; long-term (quarters–years): structural share loss to nimble indie brands or ongoing cost deflation. Hidden dependency: earnings sensitive to travel-retail and Mainland China flows that are not disclosed in the release.

Trade implications: Direct play—small, conditional long on 002790.KS given revenue growth but margin risk; prefer option-defined exposure. Relative-value: pair long Amorepacific vs short LG Household & Health Care (051900.KS) to capture margin improvement vs premium peer valuation. Cross-asset: tighter KRW or higher rates would compress multiples; consider buying 6–12 month call spreads rather than outright stock to limit downside.

Contrarian angles: Consensus may price prolonged margin slump; that underestimates management's ability to rationalize SKUs and cut SG&A — a 100–200bp margin recovery would lift EPS >25% annually. Reaction is not fully priced: market moved only ~2% intraday despite large operating-income decline, implying asymmetric upside if company provides concrete margin guidance in next quarter. Historical parallel: post-2019 cosmetics downturn where branded players staged 6–9 month recoveries after SKU rationalization.

Key Decisions for Investors

• Establish a 2–3% notional long position in Amorepacific (002790.KS) within 1–4 weeks, target a 20% upside (≈KRW 14,500) over 6–12 months conditional on operating margin improvement ≥100bp next quarter; set a stop-loss at -10% (≈KRW 10,944).
• Implement a relative-value pair: long 002790.KS and short LG Household & Health Care (051900.KS) at a 0.7 notional ratio to neutralize sector beta; target 8–12% relative outperformance in 3–6 months, cut pair if Amorepacific underperforms its peer by >6% in 60 days.
• Buy a 9–12 month call spread on 002790.KS (buy KRW 14,000 call, sell KRW 18,000 call) sized to 0.5–1% of portfolio to capture upside while capping premium; if options unavailable, buy 9–12 month LEAPS-equivalent or sell 6-month covered calls at KRW 15,000 if initiating stock exposure.
• Trim high-valuation consumer-beauty exposure: reduce LG Household & Health Care (051900.KS) weight by 3–5% and redeploy proceeds into the Amorepacific long and 6–12 month KOSPI consumer staples exposure; reassess after next quarterly guide or if Chinese retail sales for cosmetics fall below +2% YoY over a 30–60 day window.